Trial Information
The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin
Inclusion Criteria:
- Cancer patients in complete remission after treatment, with serial elevation of serum
tumor markers and negative CT or other conventional imaging test.
- Patients with newly diagnosed metastatic cancer with unknown primary tumor
- Glucose levels below 150-200
- Patient signed informed consent
Exclusion Criteria:
- Pregnant or lactating women
- Patient unable or not willing to tolerate the test until its completion
- One or more of the inclusion criteria is not fulfilled
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
the impact of the imaging modality on patient management
Principal Investigator
Rachel Bar-Shalom, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Rambam Health Care Campus
Authority:
Israel: Israeli Health Ministry Pharmaceutical Administration
Study ID:
hybridCTIL
NCT ID:
NCT00396916
Start Date:
December 2004
Completion Date:
Related Keywords: